Metagenomi Therapeutics — Third Quarter 2026 Earnings Summary

Metagenomi Therapeutics has received FDA clearance for its Investigational New Drug application for MGX-001, a one-time genome editing treatment designed to provide durable Factor VIII activity for patients with hemophilia A. The company plans to initiate the global INTEGR8 Phase 1/2 clinical trial in the first half of 2027 and expects to report initial safety and efficacy data in the second half of that year. For the third quarter ended September 30, 2026, the company reported $101.7 million in cash and cash equivalents, with an anticipated operational runway extending into 2028. During this period, research and development expenses totaled $17.5 million, while general and administrative expenses reached $6.9 million, including a $1.2 million one-time litigation settlement.